000151379 001__ 151379
000151379 005__ 20251017144628.0
000151379 0247_ $$2doi$$a10.3390/vaccines9060567
000151379 0248_ $$2sideral$$a127259
000151379 037__ $$aART-2021-127259
000151379 041__ $$aeng
000151379 100__ $$aMesonero-Escuredo S.
000151379 245__ $$aEffect of edema disease vaccination on mortality and growth parameters in nursery pigs in a shiga toxin 2e positive commercial farm
000151379 260__ $$c2021
000151379 5060_ $$aAccess copy available to the general public$$fUnrestricted
000151379 5203_ $$aDiseases caused by Escherichia coli are recognized as major problems in the swine industry, one of them being edema disease (ED). Importantly, the current decrease in antibiotic use may cause difficulties in controlling the disorders caused by E. coli. Therefore, this study assessed the efficacy of a commercial vaccine against ED in nursery pigs from a farm with previous history of ED. A total of 1344 pigs were monitored, half of them were randomly assigned to a vaccinated group (VG) and the other half to a non-vaccinated group (NVG). The vaccine was administered at 7 days of age. Animals received a pre-starter feed with 2500 ppm of zinc oxide (ZnO) for 2 weeks and a starter feed without ZnO for another 3 weeks. Pen-group weights were recorded at 28 (weaning), 42 (end of pre-starter phase), and 63 days of life (end of nursery phase). Death/culling rates, average daily gain (ADG), and average daily feed intake (ADFI) were calculated for each group at each phase. The overall relative risk of dying/being culled for a pig in the NVG was 5 times higher than that of the VG group but increased to 12 times higher during the starter period. ADG and ADFI were also significantly higher in the VG group for that period. Vaccination against ED significantly reduced pig losses and improved ADG and ADFI, particularly when ZnO was not used.
000151379 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttps://creativecommons.org/licenses/by/4.0/deed.es
000151379 590__ $$a4.961$$b2021
000151379 591__ $$aMEDICINE, RESEARCH & EXPERIMENTAL$$b59 / 139 = 0.424$$c2021$$dQ2$$eT2
000151379 591__ $$aIMMUNOLOGY$$b77 / 162 = 0.475$$c2021$$dQ2$$eT2
000151379 592__ $$a1.004$$b2021
000151379 593__ $$aDrug Discovery$$c2021$$dQ1
000151379 593__ $$aPharmacology$$c2021$$dQ1
000151379 593__ $$aInfectious Diseases$$c2021$$dQ1
000151379 593__ $$aImmunology$$c2021$$dQ1
000151379 594__ $$a4.5$$b2021
000151379 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000151379 700__ $$aMorales J.
000151379 700__ $$0(orcid)0000-0001-5442-7702$$aMainar-Jaime R.C.$$uUniversidad de Zaragoza
000151379 700__ $$aDíaz G.
000151379 700__ $$aArnal J.L.
000151379 700__ $$aCasanovas C.
000151379 700__ $$aBarrabés S.
000151379 700__ $$aSegalés J.
000151379 7102_ $$11009$$2773$$aUniversidad de Zaragoza$$bDpto. Patología Animal$$cÁrea Sanidad Animal
000151379 773__ $$g9, 6 (2021), 567 [7 pp.]$$tVaccines$$x2076-393X
000151379 8564_ $$s263665$$uhttps://zaguan.unizar.es/record/151379/files/texto_completo.pdf$$yVersión publicada
000151379 8564_ $$s2690611$$uhttps://zaguan.unizar.es/record/151379/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000151379 909CO $$ooai:zaguan.unizar.es:151379$$particulos$$pdriver
000151379 951__ $$a2025-10-17-14:25:08
000151379 980__ $$aARTICLE